3/10
09:34 am
halo
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here's Why [Yahoo! Finance]
Low
Report
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here's Why [Yahoo! Finance]
3/6
08:12 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright.
2/26
08:30 am
halo
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Low
Report
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
2/20
09:39 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $75.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $75.00 price target on the stock.
2/19
07:07 pm
halo
More on HALO's Q4 Earnings [Yahoo! Finance]
Low
Report
More on HALO's Q4 Earnings [Yahoo! Finance]
2/19
08:00 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $70.00 to $72.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $70.00 to $72.00. They now have a "buy" rating on the stock.
2/19
06:43 am
halo
Halozyme Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Halozyme Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/18
06:22 pm
halo
Halozyme Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/18
04:44 pm
halo
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS [Yahoo! Finance]
Low
Report
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS [Yahoo! Finance]
2/18
04:01 pm
halo
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Low
Report
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
2/14
11:51 am
halo
Halozyme rated overweight by Morgan Stanley, diversified revenue cited [Seeking Alpha]
Neutral
Report
Halozyme rated overweight by Morgan Stanley, diversified revenue cited [Seeking Alpha]
2/13
12:57 pm
halo
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know [Yahoo! Finance]
Low
Report
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know [Yahoo! Finance]
2/4
08:30 am
halo
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
Low
Report
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
2/4
08:00 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
2/3
07:30 am
halo
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Low
Report
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
1/13
10:30 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at Wells Fargo & Company from $62.00 to $57.00. They now have an "equal weight" rating on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at Wells Fargo & Company from $62.00 to $57.00. They now have an "equal weight" rating on the stock.
1/10
12:47 pm
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Piper Sandler from $52.00 to $53.00. They now have a "neutral" rating on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Piper Sandler from $52.00 to $53.00. They now have a "neutral" rating on the stock.
1/10
08:03 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $68.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $68.00 to $70.00. They now have a "buy" rating on the stock.
1/8
05:34 pm
halo
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks [Yahoo! Finance]
Low
Report
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks [Yahoo! Finance]
1/8
05:34 pm
halo
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance [Yahoo! Finance]
Low
Report
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance [Yahoo! Finance]
1/8
09:53 am
halo
Halozyme raises 2025 guidance, announces $250M stock buyback [Seeking Alpha]
Low
Report
Halozyme raises 2025 guidance, announces $250M stock buyback [Seeking Alpha]
1/8
07:00 am
halo
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Medium
Report
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
1/6
09:09 am
halo
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance [Yahoo! Finance]
Medium
Report
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance [Yahoo! Finance]
1/6
08:30 am
halo
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Medium
Report
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
12/30
11:10 am
halo
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]
Low
Report
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]